The ongoing TALAPRO-2 study is looking at the combination of two medicines called talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer. This plain language summary provides an overview of the study protocol published in Future Oncology.
Read the full article here.
The original article on which this summary is based is called ‘Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design’ and was originally published in the journal Future Oncology. The original article can be read here.